Roche Diagnostics introduces new molecular laboratory instrument in the UK

Roche Diagnostics has launched its new molecular laboratory instrument, the cobas® 5800 System, in the UK. Through improved automation the new system can help raise testing volumes, improve operational efficiency and manage the increasing demand that many laboratories are experiencing.

The system has a small footprint making it accessible to many more laboratories, particularly those with less space. The fully automated system, which consolidates 90% of routine testing on a single platform, minimizes laboratory workers’ hands-on time and improves productivity. The system provides a scalable solution for smaller labs seeking big lab performance, or for bigger labs seeking small lab agility.

The cobas® 5800 will be available for demos at the Institute of Biomedical Science (IBMS) Congress on 14-17 March 2022.

The processing digital platform it uses, the Molecular Work Area, currently performs over 10 million tests per month on more than 1,000 installed systems around the world.

Geoff Twist, Managing Director of Roche Diagnostics UK and Ireland said:

“Clinicians and patients rely on accurate and timely results to make informed decisions, and in vitro testing on systems like the cobas® 5800 play a crucial role in helping the NHS to provide these results in a highly pressurized environment.

“The NHS is facing another exceptionally challenging period - as it continues to respond to COVID-19 whilst also tackling the huge backlog of patients which has built up during the pandemic - and we’re delighted to bring the compact cobas® 5800 to the UK market at a time when labs up and down the country are working harder than ever."

The need for flexible, reliable, fully-automated diagnostic solutions has never been more acute. By building on a system with proven reliability and performance, we continue to simplify laboratory operations to help ensure patients are diagnosed and put on the right treatment pathway as quickly as possible.”

Geoff Twist, Managing Director of Roche Diagnostics UK and Ireland

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Roche Sequencing and Life Science. (2023, April 14). Roche Diagnostics introduces new molecular laboratory instrument in the UK. News-Medical. Retrieved on December 21, 2024 from https://www.news-medical.net/news/20220308/Roche-Diagnostics-introduces-new-molecular-laboratory-instrument-in-the-UK.aspx.

  • MLA

    Roche Sequencing and Life Science. "Roche Diagnostics introduces new molecular laboratory instrument in the UK". News-Medical. 21 December 2024. <https://www.news-medical.net/news/20220308/Roche-Diagnostics-introduces-new-molecular-laboratory-instrument-in-the-UK.aspx>.

  • Chicago

    Roche Sequencing and Life Science. "Roche Diagnostics introduces new molecular laboratory instrument in the UK". News-Medical. https://www.news-medical.net/news/20220308/Roche-Diagnostics-introduces-new-molecular-laboratory-instrument-in-the-UK.aspx. (accessed December 21, 2024).

  • Harvard

    Roche Sequencing and Life Science. 2023. Roche Diagnostics introduces new molecular laboratory instrument in the UK. News-Medical, viewed 21 December 2024, https://www.news-medical.net/news/20220308/Roche-Diagnostics-introduces-new-molecular-laboratory-instrument-in-the-UK.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Roche receives Breakthrough Device Designation from FDA for new Alzheimer's disease assays